Nam Vo, MD
Nephrology · Asheville, NCNPI 1255382214
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $72,925 of the $89,072 with a category attached, or 81.9%. 13 manufacturers reported payments, led by Bayer at 31.2% of the total. Among nephrology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $553.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$28K
- Lilly USA, LLC$25K
- Boehringer Ingelheim$14K
- Travere Therapeutics, Inc.$14K
- Novartis$7K
- AstraZeneca$404
- plus $662 from 7 others
Across 133 payments — averaging $1731.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$131K
- AstraZeneca$31K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$25K
- Novartis$22K
- Bayer$20K
- Ironwood Pharmaceuticals, Inc$1K
What the payments were for
- Consulting fees$8,0099%
- Speaking & faculty fees$72,92582%
- Travel & lodging$4,4375%
- Food & beverage$3,6254%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 27 | $27,798 |
| Lilly USA, LLC | 39 | $25,378 |
| Boehringer Ingelheim | 20 | $13,714 |
| Travere Therapeutics, Inc. | 37 | $13,698 |
| Novartis | 20 | $7,418 |
| AstraZeneca(2 entities) | 3 | $404 |
| Abbott | 1 | $194 |
| Medtronic | 2 | $151 |
| Amgen | 7 | $147 |
| Baxter Healthcare | 1 | $66 |
| BD | 1 | $39 |
| Vifor Pharma, Inc. | 2 | $38 |
| Nxstage Medical, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,072 in reported general payments places this provider in the 95th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 494 | $456,076 |
| FarxigaDapagliflozin Propanediol | 318 | $291,182 |
| KerendiaFinerenone | 173 | $181,101 |
| XphozahTenapanor Hcl | 19 | $69,052 |
| VelphoroSucroferric Oxyhydroxide | 12 | $19,293 |
| EliquisApixaban | 14 | $8,332 |
| ProsolParenteral Amino Acid 20% No.1 | 43 | $7,638 |
| Torsemide | 273 | $6,143 |
| Calcitriol | 409 | $4,842 |
| Sevelamer Carbonate | 25 | $4,406 |
| Chlorthalidone | 297 | $4,193 |
| Eplerenone | 51 | $4,097 |
| Spironolactone | 558 | $3,538 |
| Bumetanide | 88 | $3,525 |
| Telmisartan | 147 | $2,755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $13,714 | $456,076494 claims |
| AstraZenecaFarxiga | $404 | $291,182318 claims |
| BayerKerendia | $27,798 | $181,101173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 366 nephrology providers in North Carolina.
Other nephrology in Asheville
- Gregory GreenwoodWinston-Salem$947K
- Michael EtomiCharlotte$212K
- William KendrickGreenville$125K
- Jason EckelCary$123K
- Raven VooraSanford$111K
- Jennifer StoddardPinehurst$77K
- Barry FreedmanWinston Salem$67K
- James McCabeWilmington$56K
- Sammy MoghaziRaleigh$56K
- Matthew EllisDurham$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.